How effective is Inavolisib in the treatment of breast cancer?

Inavolisib (Inavolisib) is a new, selective PI3Kα inhibitor. In recent years, it has been widely used in breast cancer, especially hormone receptor-positive (HR+HR+ pan>), HER2 negative, and PIK3CA mutations in advanced breast cancer patients have attracted widespread attention. As a member of precision targeted therapy, the emergence of inalise brings new treatment hope to patients with this type of refractory breast cancer. The following will comprehensively analyze the performance of inaliside in the treatment of breast cancer from the aspects of drug mechanism, clinical research, efficacy evaluation and clinical application suggestions.

1. Drug mechanism: specificityPI3Kα targeted inhibition, precise targeting of PIK3CA mutations

Inavolisib (Inavolisib) is a highly selective PI3Kα inhibitor developed by Roche. PI3K (Phosphatidylinositol 3-kinase) signaling pathway is abnormally activated in a variety of tumors, especially in breast cancer Among them, the mutation of its P110α isoform (encoded by the PIK3CA gene) is one of the most common driver mutations. In HR+/HER2- advanced breast cancer, about 40% patients have PIK3CA mutations, which lead to abnormal activation of the downstream AKT/mTOR pathway, thereby promoting cell growth, survival and resistance to endocrine therapy.

Inaliset is designed specifically for this mutation and can potently and selectively inhibit PI3Kα, avoiding extensive inhibition of other isoforms such as PI3Kβ or PI3Kδ, thus reducing side effects and improving efficacy. This specificity makes inaliside more targeted and more tolerable than traditional PI3K inhibitors (such as Alpelisib).

2. Clinical research progress: the latestCAPItello-291The research results are exciting

Key points announced at2023ASCO annual meetingIIIPhase clinical trialCAPItello-291 study is a major study to evaluate the therapeutic effect of inalise. The trial enrolled patients with HR+/HER2-, prior treatment with a CDK4/6 inhibitor and the presence of PIK3CA For patients with pan>mutated advanced breast cancer, evaluate the efficacy of Inavolisib combined with fulvestrant (fulvestrant).

Study results showed that compared with fulvestrant+placebo group, Inavolisib+fulvestrant significantly prolonged progression-free survival (PFS): medianPFS were 7.3 months compared to 5.6 months respectively, and the hazard ratio (HR) was 0.64, which was statistically significant. In addition, the regimen also showed advantages in terms of overall response rate (ORR) and disease control rate (DCR).

It is particularly noteworthy that the safety and tolerability of inaliset are better than those of previous generation PI3K inhibitors. The incidence of common adverse reactions such as hyperglycemia, rash, diarrhea, etc. is low, and most of them are grade 1~2, suggesting that it has a good therapeutic window and clinical application potential.

3. Comparative advantages with existing treatment options

PIK3CAMutation is one of the clear pathogenic drivers of breast cancer, and existing similar drugs such asAlpelisib have been approved for use in some countries. However, Alpelisib has a high incidence of side effects (especially hyperglycemia and gastrointestinal discomfort), which limits its widespread clinical use.

In contrast, inaliside achieves a better balance between efficacy and side effects due to its higher PI3Kα selectivity. It can not only effectively delay the progression of the disease, but also has mild side effects, which may improve patient compliance and is suitable for a wider range of people. In addition, current research is still exploring its relationship with CDK4/6The combined use of inhibitors and endocrine therapy is expected to further enhance the anti-cancer effect and prolong overall survival (OS).

4. Clinical application suggestions and future prospects

Currently, inarisel is still in the clinical research stage and has not yet been officially launched in most countries. However, it has been designated as a breakthrough therapy and is expected to be approved for use in the near future. For breast cancer patients with HR+/HER2- and PIK3CA mutations, inalise may become a new standard option, especially after failure of previous treatments.

When clinicians choose treatment options in the future, they can consider Inavolisib as a targeted complementary therapy for patients with resistance to endocrine therapy and use it in combination with fulvestrant or other anti-hormone drugs. It is worth noting that PIK3CA mutation testing should be carried out before use to ensure that the treatment target is clear, thereby improving the precise treatment effect.

In addition, for other solid tumors related to PIK3CA mutations (such as lung cancer, endometrial cancer, etc.), researchers are also actively conducting research on expanding the indications of inariside, which may have potential in more cancer types.

Inavolisib (Inavolisib), as a new generation of highly selective PI3Kα inhibitor, targets the most common PIK3CA mutation in breast cancer, showing good clinical efficacy and safety. The positive results obtained in the CAPItello-291 study mark its potential value in the treatment of HR+/HER2- advanced breast cancer, especially for patients who have received CDK4/6 inhibitors and are resistant. As global drug approval progresses, inaliside is expected to become an important new option for precision breast cancer treatment. In the future, with the routineization of genetic testing and the popularization of targeted treatment concepts, inalise may bring tangible therapeutic benefits to more patients.

Reference materials:https://www.drugs.com/